昆药集团
(600422)
| 流通市值：163.51亿 | | | 总市值：163.54亿 |
| 流通股本：7.57亿 | | | 总股本：7.57亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,852,637,983.31 | 7,703,121,256.83 | 5,610,863,771.76 | 3,770,638,315.78 |
| 营业收入 | 1,852,637,983.31 | 7,703,121,256.83 | 5,610,863,771.76 | 3,770,638,315.78 |
| 二、营业总成本 | 1,681,940,225.73 | 7,153,005,232.63 | 5,165,454,500.49 | 3,497,605,652.32 |
| 营业成本 | 1,089,547,848.12 | 4,250,580,509.27 | 3,082,532,545.29 | 2,074,750,344.28 |
| 税金及附加 | 16,418,280.81 | 74,707,054.84 | 54,065,184.74 | 35,154,873.89 |
| 销售费用 | 476,962,083.94 | 2,432,640,868.01 | 1,742,085,743.45 | 1,187,620,048.17 |
| 管理费用 | 75,456,728.58 | 313,544,474.81 | 233,986,346.31 | 163,705,679.74 |
| 研发费用 | 17,215,457.38 | 71,263,309.76 | 43,325,919.08 | 30,575,426.3 |
| 财务费用 | 6,339,826.9 | 10,269,015.94 | 9,458,761.62 | 5,799,279.94 |
| 其中:利息费用 | 6,565,939.91 | 21,589,962.71 | 11,351,624.27 | 14,381,268.95 |
| 其中:利息收入 | 1,744,026.06 | 12,048,361.25 | 2,667,406.97 | 6,055,857.88 |
| 加:公允价值变动收益 | -321,823.57 | 1,026,092.86 | -6,598,765.58 | -3,557,179.14 |
| 加:投资收益 | 776,466.59 | 17,312,225.9 | 15,452,073.68 | 13,561,087.29 |
| 资产处置收益 | 267,965.77 | 978,266.91 | 1,523,520.65 | 1,251,910.92 |
| 资产减值损失(新) | -6,269,577.01 | -65,934,507.71 | -13,813,752.11 | -10,932,168.99 |
| 信用减值损失(新) | -25,586,938.09 | -52,858,543.98 | -40,933,747.2 | -28,513,177.9 |
| 其他收益 | 7,982,842.32 | 117,856,325.9 | 75,401,595.68 | 37,275,909.34 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 147,546,693.59 | 568,495,884.08 | 476,440,196.39 | 282,119,044.98 |
| 加:营业外收入 | 751,024.9 | 6,062,271.45 | 7,643,626.61 | 6,818,749.65 |
| 减:营业外支出 | 503,269.55 | 10,938,256.39 | 7,307,230.35 | 5,506,603.1 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 147,794,448.94 | 563,619,899.14 | 476,776,592.65 | 283,431,191.53 |
| 减:所得税费用 | 26,822,788.99 | 109,477,183.59 | 80,551,290.7 | 52,904,146.47 |
| 六、净利润 | 120,971,659.95 | 454,142,715.55 | 396,225,301.95 | 230,527,045.06 |
| 持续经营净利润 | 120,971,659.95 | 454,142,715.55 | 396,225,301.95 | 230,527,045.06 |
| 归属于母公司股东的净利润 | 118,693,454.55 | 444,679,961.22 | 386,007,605.81 | 223,369,852.53 |
| 少数股东损益 | 2,278,205.4 | 9,462,754.33 | 10,217,696.14 | 7,157,192.53 |
| (一)基本每股收益 | 0.16 | 0.59 | 0.51 | 0.29 |
| (二)稀释每股收益 | 0.16 | 0.59 | 0.51 | 0.29 |
| 八、其他综合收益 | -104,249.48 | -7,802,549.3 | -1,085,751.36 | 600,365.65 |
| 归属于母公司股东的其他综合收益 | -104,249.48 | -7,907,329.72 | -1,085,751.36 | 615,932.83 |
| 九、综合收益总额 | 120,867,410.47 | 446,340,166.25 | 395,139,550.59 | 231,127,410.71 |
| 归属于母公司股东的综合收益总额 | 118,589,205.07 | 436,772,631.5 | 384,921,854.45 | 223,985,785.36 |
| 归属于少数股东的综合收益总额 | 2,278,205.4 | 9,567,534.75 | 10,217,696.14 | 7,141,625.35 |
| 公告日期 | 2024-04-20 | 2024-03-22 | 2023-10-28 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |